HomeACADEMIA
ACADEMIA

Cancer Society to Issue New Lung Cancer Treatment GL in December; Positioning of Anti-PD-1 Antibodies Will Be Focus of Interest
(Oct.31.2016)

The Japan Lung Cancer Society (JLCS) is in the process of finalizing its 2016 guidelines for the treatment of lung cancer. How the guidelines position the anti-PD-1 antibodies Opdivo (nivolumab; Ono Pharmaceutical) and Keytruda (pembrolizumab; MSD), which have shown contrasting outcomes as first-line monotherapies for the treatment of non-small cell lung cancer (NSCLC) in PIII clinical trials, is likely to be a focus of interest ...
(LOG IN FOR FULL STORY)

News Calendar